SS-31 (elamipretide) holds an unusual place in the peptide world: it is the only mitochondria-targeted peptide with a marketing approval anywhere, and yet the trial that earned that approval randomised just 12 people — and missed both of its primary endpoints. Most SS-31 research write-ups stop at "FDA approved, September 2025". The more useful question for anyone reading about ss-31 research in 2026 is what happens next, because that approval was explicitly conditional, and the study meant to confirm it only began dosing patients in July 2026.

This post walks through what was actually approved, what the underlying data does and doesn't show, and where Australia sits. For the compound background, see our SS-31 profile.

What Is SS-31, and What Exactly Was Approved?

SS-31 is a short, cell-permeable tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin — a phospholipid that helps organise the electron transport chain and maintain cristae architecture. The proposed effect is better electron transport efficiency and less reactive-species leak. That is the mechanism story, and it is well-described in biochemistry; it is not itself evidence of clinical benefit.

On 19 September 2025, the FDA granted accelerated approval to elamipretide as Forzinity, for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. This followed an earlier complete response letter and a resubmitted application. It is the first approved therapy for Barth syndrome and the first approved drug that directly targets mitochondria.

Three constraints matter and are routinely dropped from summaries:

  • The indication is one ultra-rare genetic disease, not fatigue, not ageing, not sports recovery.
  • The approved claim is muscle strength, based on an intermediate clinical endpoint — knee extensor strength — not survival, cardiac outcomes or quality of life.
  • Its separate phase 3 in primary mitochondrial myopathy (MMPOWER-3) missed both endpoints, which is the closest thing we have to a large, well-powered test of SS-31 in a broader muscle-fatigue population.

The 12-Patient Trial Behind the First Mitochondrial Drug Approval

The pivotal study, TAZPOWER, enrolled 12 genetically confirmed Barth syndrome patients aged 12 and over, weighing more than 30 kg. It used a crossover design: 40 mg subcutaneous elamipretide daily for 12 weeks, a four-week washout, then 12 weeks on the opposite arm.

The randomised phase did not meet its primary endpoints

In the placebo-controlled portion, elamipretide did not significantly improve six-minute walk distance or total fatigue score on the Barth syndrome symptom assessment. Both primary endpoints were negative. That is not a nuance — it is the only genuinely blinded, placebo-controlled read in the programme.

The gains appeared in the open-label extension

Ten of the 12 patients entered a 168-week open-label extension; eight completed the week-168 assessment. There, six-minute walk distance improved by a cumulative 96.1 m at week 168 (P = .003), fatigue scores sat below baseline at every time point, and knee extensor strength improved by more than 45%. Those results were published in Genetics in Medicine in 2024.

Open-label extensions have no placebo arm, no blinding and heavy selection for patients who tolerated and stayed on the drug. In an ultra-rare disease with a dozen participants, that may be the best achievable evidence — but it remains uncontrolled data, and the regulator treated it as such by approving conditionally rather than fully.

Accelerated Approval Is a Conditional Verdict, Not a Final One

Accelerated approval obliges the sponsor to run a post-approval randomised, double-blind, placebo-controlled trial confirming that the strength signal translates into meaningful clinical benefit. Continued approval can be withdrawn if it doesn't.

That trial now exists. 4TAZPower (SPIBA-401, NCT07531251) is a post-marketing phase 3b/4 randomised, double-blind, parallel-group, placebo-controlled study of once-daily subcutaneous elamipretide over 72 weeks in genetically confirmed Barth syndrome, open to participants aged five and over. The sponsor announced the first patient dosed on 8 July 2026 — a company press release, not peer-reviewed data. The sponsor is the company formerly known as Stealth BioTherapeutics, which renamed itself Mighty Therapeutics in June 2026; it is a real, commercial-stage biotech, which is worth stating given how many fictional demonstration records now clutter trial registries for peptides.

Practically: a 72-week trial that started dosing in mid-2026 will not report before roughly 2029. Until then, SS-31's only approval rests on a strength endpoint that has never been confirmed against placebo in a parallel-group study.

SS-31 Australia: Is SS-31 Legal in Australia?

No SS-31 or elamipretide product is on the Australian Register of Therapeutic Goods. FDA approval confers nothing here — Forzinity has no Australian marketing authorisation, and Australia's mitochondrial disease community has noted that the newly approved US mito medicines are not available locally.

That leaves the same pathways as any other unapproved therapeutic good: the TGA's Special Access Scheme for a single named patient, or the Authorised Prescriber scheme for a defined patient group — both doctor-initiated, both requiring justification, neither a consumer channel. Separately, elamipretide is a prescription substance; the research-grade vials marketed online are not the approved product, are not TGA-assessed for identity, purity or sterility, and supplying them for human use in Australia is not lawful. We don't discuss sourcing, and nothing here is a recommendation.

Reading SS-31 Claims Without Getting Ahead of the Data

The longevity framing around SS-31 — restoring mitochondrial function in aged muscle, heart and kidney — comes overwhelmingly from rodent and cell work. That preclinical literature is substantial and genuinely interesting, but it has not produced a positive, replicated, placebo-controlled human outcome trial in any non-rare-disease population. The one large human trial outside rare disease, in primary mitochondrial myopathy, failed.

So the honest 2026 summary is narrow: one conditional approval, in one ultra-rare disease, on one intermediate endpoint, with confirmation pending. Claims of "15–25% improvements in cardiac function" circulating on vendor blogs do not trace to any published trial we could verify, and should be treated as marketing.

Browse other compounds in our peptides library, or join the free updates list for plain-English summaries as the 4TAZPower and dry-AMD programmes report.

FAQ

Is SS-31 (elamipretide) FDA approved?

Yes, but narrowly. It received accelerated approval on 19 September 2025 as Forzinity, to improve muscle strength in Barth syndrome patients weighing at least 30 kg. It is not approved for ageing, fatigue, fitness or any other indication.

Is SS-31 legal in Australia?

There is no SS-31 or elamipretide product on the ARTG. It is an unapproved prescription substance here, accessible only case-by-case through TGA pathways such as the Special Access Scheme or Authorised Prescriber scheme, initiated by a doctor.

What did the SS-31 Barth syndrome trial actually show?

In the 12-patient randomised crossover phase of TAZPOWER, neither primary endpoint — six-minute walk distance or total fatigue score — was met. The improvements in walk distance (96.1 m at week 168) and knee extensor strength came from an uncontrolled open-label extension with eight completers.

Does SS-31 work for anti-ageing?

There is no human trial evidence that SS-31 slows ageing or extends healthspan. The anti-ageing case rests on animal and cell studies, and its one large trial in a broader muscle-fatigue population, primary mitochondrial myopathy, missed both endpoints.

Sources

Not medical advice. SS-31 (elamipretide) holds US accelerated approval only for Barth syndrome and is not on the ARTG — it is unapproved in Australia. retatrutide.net.au is independent and not affiliated with any manufacturer.